A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer

This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.

Trial Details

NCT ID
NCT06974929
Phase
PHASE1 / PHASE2
Sponsor
Jiangsu HengRui Medicine Co., Ltd.
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • HRS-6209 Capsules
  • Letrozole Tablets
  • HRS-2189 Tablets
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Women aged 18-75 years.
  • ECOG performance status 0-1.
  • Menopausal status.
  • Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →